<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03937570</url>
  </required_header>
  <id_info>
    <org_study_id>1397CESC</org_study_id>
    <nct_id>NCT03937570</nct_id>
  </id_info>
  <brief_title>Effects of Echo-optimization of Left Ventricular Assist Devices on Functional Capacity (VAFRACT)</brief_title>
  <acronym>VAFRACT</acronym>
  <official_title>The Effects of Echo-optimization of Left Ventricular Assist Devices on Functional Capacity, a RAndomized Controlled Trial (VAFRACT)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Universita di Verona</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Universita di Verona</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      After the implantation of a left ventricular assist device (LVAD), many patients continue to&#xD;
      experience exercise intolerance. LVAD echo guided optimization (EO) determines a more&#xD;
      favorable hemodynamic profile and could provide an improvement on functional capacity (FC).&#xD;
      VAFRACT is a prospective randomized trial to evaluate the additional benefit of an EO&#xD;
      approach on FC, measured by cardiopulmonary exercise test (CPET), in LVAD optimization free&#xD;
      population.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The use of Left Ventricular Assist Devices (LVAD) is a viable therapeutic option to improve&#xD;
      survival and quality of life of patients with advanced and refractory heart failure (HF).&#xD;
      However, after the implantation of an LVAD, patients' functional capacity (FC) is still&#xD;
      reduced with maximum oxygen uptake (VO2 peak) values calculated at the cardiopulmonary&#xD;
      exercise test (CPET) ranging from 11 to 20 ml/kg/min. LVAD echo guided optimization (EO)&#xD;
      determines a more favorable hemodynamic profile, in particular for the right ventricle, and&#xD;
      could provide an improvement on FC. VAFRACT is a prospective randomized trial to evaluate the&#xD;
      additional benefit of an EO approach on FC, measured by CPET in LVAD optimization free&#xD;
      population.&#xD;
&#xD;
      The optimal device speed is defined as the one that allows an intermittent aortic valve&#xD;
      opening and a neutral position of the interventricular septum without increasing aortic or&#xD;
      tricuspid regurgitation associated or not to a dilatation of the right ventricle (RV). In&#xD;
      this condition it is reasonable to expect a more favorable hemodynamic profile for the RV and&#xD;
      a better response in terms of functional capacity.&#xD;
&#xD;
      Subjects studied are HF patients supported with a continuous-flow LVAD: HeartMate II&#xD;
      (Thoratec Inc., Pleasanton, CA) and HeartMate 3 (HM 3, Abbott, North Chicago, IL). Patients&#xD;
      are recruited from our Day Hospital of the Cardiac Surgery Department at the University&#xD;
      Hospital of Verona.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 8, 2018</start_date>
  <completion_date type="Actual">August 31, 2020</completion_date>
  <primary_completion_date type="Actual">December 30, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>VO2 Peak</measure>
    <time_frame>three months</time_frame>
    <description>peak oxygen uptake measured by cardiopulmonary exercise test</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With LVAD-related Hospitalizations</measure>
    <time_frame>Three months</time_frame>
    <description>Rate of hospitalizations for: device thrombosis, hemorrhagic events, infections, right heart failure, arrhythmias.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>QoL: The EQ-5D Questionnaire</measure>
    <time_frame>Three months</time_frame>
    <description>Changes in quality of life perceived by EuroQoL (quality of life) Scale. It is an instrument which evaluates the quality of life measuring with one question: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. The answers given to these question (1 = no problems; 2 = some problems; 3 = extreme problems) are converted into EQ-5D index, an utility scores anchored at 0 for death and 1 for perfect health. The EQ-5D questionnaire also includes a Visual Analog Scale (VAS), by which respondents can report their perceived health status with a grade ranging from 0 (the worst possible health status) to 100 (the best possible health status).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Nt-proBNP</measure>
    <time_frame>Three months</time_frame>
    <description>Nt-proBNP levels</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Right Ventricular Function</measure>
    <time_frame>Three months</time_frame>
    <description>Fractional area change of right ventricle assessed by echocardiography</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CPET Exercise Time</measure>
    <time_frame>Three months</time_frame>
    <description>Cardiopulmonary exercise time</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">27</enrollment>
  <condition>Heart Failure</condition>
  <arm_group>
    <arm_group_label>EO GROUP</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients underwent LVAD echo-optimization; the optimal device speed is confirmed at the end of procedure.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CONTROL GROUP</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Patients underwent LVAD echo-optimization, but the optimal device speed is not confirmed at the end of procedure.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>echo-optimization</intervention_name>
    <description>LVAD echo-optimization consists of routine comprehensive transthoracic echocardiography at the baseline speed setting, followed by stepwise incremental adjustments to the LVAD speed (revolutions per minute: rpm), with collection of prespecified echocardiographic parameters at each new speed (eg, left ventricle end-diastolic diameter, interventricular septal position, aortic valve opening frequency/duration, tricuspid and/or mitral regurgitation severity). The optimal velocity is defined as the one that allows an intermittent aortic valve opening and a neutral position of the interventricular septum without increasing aortic or tricuspid regurgitation, associated or not to a dilatation of the right ventricle. The recommended speed range varies according to the indications given in the data sheet for each specific device.</description>
    <arm_group_label>EO GROUP</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  at least 3 months after LVAD implantation;&#xD;
&#xD;
          -  compliance to the required follow-up schedule;&#xD;
&#xD;
          -  age 18 or above or of legal age to give informed consent specific to state and&#xD;
             national laws.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  distance of less than 150 meters on the six-minute walk test (6MWT) or impossibility&#xD;
             to perform CPET&#xD;
&#xD;
          -  recent finding of any major device-related complication (sepsis, thrombosis â€¦).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>MARZIA LILLIU, MD</last_name>
    <role>Principal Investigator</role>
  </overall_official>
  <location>
    <facility>
      <name>Department of Cardiac Surgery, University of Verona</name>
      <address>
        <city>Verona</city>
        <zip>37126</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>May 1, 2019</study_first_submitted>
  <study_first_submitted_qc>May 2, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">May 3, 2019</study_first_posted>
  <results_first_submitted>October 10, 2021</results_first_submitted>
  <results_first_submitted_qc>October 10, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">November 2, 2021</results_first_posted>
  <last_update_submitted>October 10, 2021</last_update_submitted>
  <last_update_submitted_qc>October 10, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 2, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Universita di Verona</investigator_affiliation>
    <investigator_full_name>Marzia Lilliu</investigator_full_name>
    <investigator_title>MD, Principal Investigator, PhD student in Cardiovascular Sciences</investigator_title>
  </responsible_party>
  <keyword>left ventricular assist device</keyword>
  <keyword>echo-optimization</keyword>
  <keyword>functional capacity</keyword>
  <keyword>cardiopulmonary exercise test</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>July 19, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/70/NCT03937570/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>EO GROUP</title>
          <description>Patients underwent LVAD echo-optimization; the optimal device speed is confirmed at the end of procedure.&#xD;
echo-optimization: LVAD echo-optimization consists of routine comprehensive transthoracic echocardiography at the baseline speed setting, followed by stepwise incremental adjustments to the LVAD speed (revolutions per minute: rpm), with collection of prespecified echocardiographic parameters at each new speed (eg, left ventricle end-diastolic diameter, interventricular septal position, aortic valve opening frequency/duration, tricuspid and/or mitral regurgitation severity). The optimal velocity is defined as the one that allows an intermittent aortic valve opening and a neutral position of the interventricular septum without increasing aortic or tricuspid regurgitation, associated or not to a dilatation of the right ventricle. The recommended speed range varies according to the indications given in the data sheet for each specific device.</description>
        </group>
        <group group_id="P2">
          <title>CONTROL GROUP</title>
          <description>Patients underwent LVAD echo-optimization, but the optimal device speed is not confirmed at the end of procedure.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
                <participants group_id="P2" count="14"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
                <participants group_id="P2" count="14"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>EO GROUP</title>
          <description>Patients underwent LVAD echo-optimization; the optimal device speed is confirmed at the end of procedure.&#xD;
echo-optimization: LVAD echo-optimization consists of routine comprehensive transthoracic echocardiography at the baseline speed setting, followed by stepwise incremental adjustments to the LVAD speed (revolutions per minute: rpm), with collection of prespecified echocardiographic parameters at each new speed (eg, left ventricle end-diastolic diameter, interventricular septal position, aortic valve opening frequency/duration, tricuspid and/or mitral regurgitation severity). The optimal velocity is defined as the one that allows an intermittent aortic valve opening and a neutral position of the interventricular septum without increasing aortic or tricuspid regurgitation, associated or not to a dilatation of the right ventricle. The recommended speed range varies according to the indications given in the data sheet for each specific device.</description>
        </group>
        <group group_id="B2">
          <title>CONTROL GROUP</title>
          <description>Patients underwent LVAD echo-optimization, but the optimal device speed is not confirmed at the end of procedure.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="13"/>
            <count group_id="B2" value="14"/>
            <count group_id="B3" value="27"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="20"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="60.3" spread="10"/>
                    <measurement group_id="B2" value="63" spread="6.4"/>
                    <measurement group_id="B3" value="61.7" spread="8.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="00"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="27"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Italy</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>VO2 peak</title>
          <units>mL/kg/min</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13.2" spread="2.5"/>
                    <measurement group_id="B2" value="13.8" spread="2.4"/>
                    <measurement group_id="B3" value="13.5" spread="2.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>VO2 Peak</title>
        <description>peak oxygen uptake measured by cardiopulmonary exercise test</description>
        <time_frame>three months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>EO GROUP</title>
            <description>Patients underwent LVAD echo-optimization; the optimal device speed is confirmed at the end of procedure.&#xD;
echo-optimization: LVAD echo-optimization consists of routine comprehensive transthoracic echocardiography at the baseline speed setting, followed by stepwise incremental adjustments to the LVAD speed (revolutions per minute: rpm), with collection of prespecified echocardiographic parameters at each new speed (eg, left ventricle end-diastolic diameter, interventricular septal position, aortic valve opening frequency/duration, tricuspid and/or mitral regurgitation severity). The optimal velocity is defined as the one that allows an intermittent aortic valve opening and a neutral position of the interventricular septum without increasing aortic or tricuspid regurgitation, associated or not to a dilatation of the right ventricle. The recommended speed range varies according to the indications given in the data sheet for each specific device.</description>
          </group>
          <group group_id="O2">
            <title>CONTROL GROUP</title>
            <description>Patients underwent LVAD echo-optimization, but the optimal device speed is not confirmed at the end of procedure.</description>
          </group>
        </group_list>
        <measure>
          <title>VO2 Peak</title>
          <description>peak oxygen uptake measured by cardiopulmonary exercise test</description>
          <units>mL/Kg/min</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>BASELINE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.2" spread="2.5"/>
                    <measurement group_id="O2" value="13.8" spread="2.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3 MONTHS-FOLLOW UP</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.2" spread="2.5"/>
                    <measurement group_id="O2" value="13.2" spread="2.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With LVAD-related Hospitalizations</title>
        <description>Rate of hospitalizations for: device thrombosis, hemorrhagic events, infections, right heart failure, arrhythmias.</description>
        <time_frame>Three months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>EO GROUP</title>
            <description>Patients underwent LVAD echo-optimization; the optimal device speed is confirmed at the end of procedure.&#xD;
echo-optimization: LVAD echo-optimization consists of routine comprehensive transthoracic echocardiography at the baseline speed setting, followed by stepwise incremental adjustments to the LVAD speed (revolutions per minute: rpm), with collection of prespecified echocardiographic parameters at each new speed (eg, left ventricle end-diastolic diameter, interventricular septal position, aortic valve opening frequency/duration, tricuspid and/or mitral regurgitation severity). The optimal velocity is defined as the one that allows an intermittent aortic valve opening and a neutral position of the interventricular septum without increasing aortic or tricuspid regurgitation, associated or not to a dilatation of the right ventricle. The recommended speed range varies according to the indications given in the data sheet for each specific device.</description>
          </group>
          <group group_id="O2">
            <title>CONTROL GROUP</title>
            <description>Patients underwent LVAD echo-optimization, but the optimal device speed is not confirmed at the end of procedure.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With LVAD-related Hospitalizations</title>
          <description>Rate of hospitalizations for: device thrombosis, hemorrhagic events, infections, right heart failure, arrhythmias.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>QoL: The EQ-5D Questionnaire</title>
        <description>Changes in quality of life perceived by EuroQoL (quality of life) Scale. It is an instrument which evaluates the quality of life measuring with one question: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. The answers given to these question (1 = no problems; 2 = some problems; 3 = extreme problems) are converted into EQ-5D index, an utility scores anchored at 0 for death and 1 for perfect health. The EQ-5D questionnaire also includes a Visual Analog Scale (VAS), by which respondents can report their perceived health status with a grade ranging from 0 (the worst possible health status) to 100 (the best possible health status).</description>
        <time_frame>Three months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>EO GROUP</title>
            <description>Patients underwent LVAD echo-optimization; the optimal device speed is confirmed at the end of procedure.&#xD;
echo-optimization: LVAD echo-optimization consists of routine comprehensive transthoracic echocardiography at the baseline speed setting, followed by stepwise incremental adjustments to the LVAD speed (revolutions per minute: rpm), with collection of prespecified echocardiographic parameters at each new speed (eg, left ventricle end-diastolic diameter, interventricular septal position, aortic valve opening frequency/duration, tricuspid and/or mitral regurgitation severity). The optimal velocity is defined as the one that allows an intermittent aortic valve opening and a neutral position of the interventricular septum without increasing aortic or tricuspid regurgitation, associated or not to a dilatation of the right ventricle. The recommended speed range varies according to the indications given in the data sheet for each specific device.</description>
          </group>
          <group group_id="O2">
            <title>CONTROL GROUP</title>
            <description>Patients underwent LVAD echo-optimization, but the optimal device speed is not confirmed at the end of procedure.</description>
          </group>
        </group_list>
        <measure>
          <title>QoL: The EQ-5D Questionnaire</title>
          <description>Changes in quality of life perceived by EuroQoL (quality of life) Scale. It is an instrument which evaluates the quality of life measuring with one question: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. The answers given to these question (1 = no problems; 2 = some problems; 3 = extreme problems) are converted into EQ-5D index, an utility scores anchored at 0 for death and 1 for perfect health. The EQ-5D questionnaire also includes a Visual Analog Scale (VAS), by which respondents can report their perceived health status with a grade ranging from 0 (the worst possible health status) to 100 (the best possible health status).</description>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>BASELINE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.796" spread="0.1"/>
                    <measurement group_id="O2" value="0.804" spread="0.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3 MONTHS-FOLLOW UP</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.85" spread="0.08"/>
                    <measurement group_id="O2" value="0.8" spread="0.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Nt-proBNP</title>
        <description>Nt-proBNP levels</description>
        <time_frame>Three months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>EO GROUP</title>
            <description>Patients underwent LVAD echo-optimization; the optimal device speed is confirmed at the end of procedure.&#xD;
echo-optimization: LVAD echo-optimization consists of routine comprehensive transthoracic echocardiography at the baseline speed setting, followed by stepwise incremental adjustments to the LVAD speed (revolutions per minute: rpm), with collection of prespecified echocardiographic parameters at each new speed (eg, left ventricle end-diastolic diameter, interventricular septal position, aortic valve opening frequency/duration, tricuspid and/or mitral regurgitation severity). The optimal velocity is defined as the one that allows an intermittent aortic valve opening and a neutral position of the interventricular septum without increasing aortic or tricuspid regurgitation, associated or not to a dilatation of the right ventricle. The recommended speed range varies according to the indications given in the data sheet for each specific device.</description>
          </group>
          <group group_id="O2">
            <title>CONTROL GROUP</title>
            <description>Patients underwent LVAD echo-optimization, but the optimal device speed is not confirmed at the end of procedure.</description>
          </group>
        </group_list>
        <measure>
          <title>Nt-proBNP</title>
          <description>Nt-proBNP levels</description>
          <units>ng/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>BASELINE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1743" spread="1453"/>
                    <measurement group_id="O2" value="1759" spread="1154"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3 MONTHS-FOLLOW UP</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1484" spread="1251"/>
                    <measurement group_id="O2" value="1538" spread="1020"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Right Ventricular Function</title>
        <description>Fractional area change of right ventricle assessed by echocardiography</description>
        <time_frame>Three months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>EO GROUP</title>
            <description>Patients underwent LVAD echo-optimization; the optimal device speed is confirmed at the end of procedure.&#xD;
echo-optimization: LVAD echo-optimization consists of routine comprehensive transthoracic echocardiography at the baseline speed setting, followed by stepwise incremental adjustments to the LVAD speed (revolutions per minute: rpm), with collection of prespecified echocardiographic parameters at each new speed (eg, left ventricle end-diastolic diameter, interventricular septal position, aortic valve opening frequency/duration, tricuspid and/or mitral regurgitation severity). The optimal velocity is defined as the one that allows an intermittent aortic valve opening and a neutral position of the interventricular septum without increasing aortic or tricuspid regurgitation, associated or not to a dilatation of the right ventricle. The recommended speed range varies according to the indications given in the data sheet for each specific device.</description>
          </group>
          <group group_id="O2">
            <title>CONTROL GROUP</title>
            <description>Patients underwent LVAD echo-optimization, but the optimal device speed is not confirmed at the end of procedure.</description>
          </group>
        </group_list>
        <measure>
          <title>Right Ventricular Function</title>
          <description>Fractional area change of right ventricle assessed by echocardiography</description>
          <units>percentage of fractional area change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>BASELINE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36.5" spread="3.8"/>
                    <measurement group_id="O2" value="35.8" spread="4.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3 MONTHS-FOLLOW UP</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36.8" spread="3.2"/>
                    <measurement group_id="O2" value="35.7" spread="4.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>CPET Exercise Time</title>
        <description>Cardiopulmonary exercise time</description>
        <time_frame>Three months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>EO GROUP</title>
            <description>Patients underwent LVAD echo-optimization; the optimal device speed is confirmed at the end of procedure.&#xD;
echo-optimization: LVAD echo-optimization consists of routine comprehensive transthoracic echocardiography at the baseline speed setting, followed by stepwise incremental adjustments to the LVAD speed (revolutions per minute: rpm), with collection of prespecified echocardiographic parameters at each new speed (eg, left ventricle end-diastolic diameter, interventricular septal position, aortic valve opening frequency/duration, tricuspid and/or mitral regurgitation severity). The optimal velocity is defined as the one that allows an intermittent aortic valve opening and a neutral position of the interventricular septum without increasing aortic or tricuspid regurgitation, associated or not to a dilatation of the right ventricle. The recommended speed range varies according to the indications given in the data sheet for each specific device.</description>
          </group>
          <group group_id="O2">
            <title>CONTROL GROUP</title>
            <description>Patients underwent LVAD echo-optimization, but the optimal device speed is not confirmed at the end of procedure.</description>
          </group>
        </group_list>
        <measure>
          <title>CPET Exercise Time</title>
          <description>Cardiopulmonary exercise time</description>
          <units>seconds</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>BASELINE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="490" spread="98"/>
                    <measurement group_id="O2" value="504" spread="103"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3 MONTHS-FOLLOW UP</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="526" spread="116"/>
                    <measurement group_id="O2" value="499" spread="107"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>3 months</time_frame>
      <group_list>
        <group group_id="E1">
          <title>EO GROUP</title>
          <description>Patients underwent LVAD echo-optimization; the optimal device speed is confirmed at the end of procedure.&#xD;
echo-optimization: LVAD echo-optimization consists of routine comprehensive transthoracic echocardiography at the baseline speed setting, followed by stepwise incremental adjustments to the LVAD speed (revolutions per minute: rpm), with collection of prespecified echocardiographic parameters at each new speed (eg, left ventricle end-diastolic diameter, interventricular septal position, aortic valve opening frequency/duration, tricuspid and/or mitral regurgitation severity). The optimal velocity is defined as the one that allows an intermittent aortic valve opening and a neutral position of the interventricular septum without increasing aortic or tricuspid regurgitation, associated or not to a dilatation of the right ventricle. The recommended speed range varies according to the indications given in the data sheet for each specific device.</description>
        </group>
        <group group_id="E2">
          <title>CONTROL GROUP</title>
          <description>Patients underwent LVAD echo-optimization, but the optimal device speed is not confirmed at the end of procedure.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Marzia Lilliu, MD, PhD</name_or_title>
      <organization>Division of Cardiac Surgery, Department of Surgery - University of Verona</organization>
      <phone>+39 3281383539</phone>
      <email>marzialilliu@gmail.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

